Pfizer Inc. (NYSE:PFE) Stake Reduced by Massmutual Trust Co. FSB ADV

Massmutual Trust Co. FSB ADV lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 158,880 shares of the biopharmaceutical company’s stock after selling 745 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Pfizer were worth $4,598,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in PFE. Wellington Management Group LLP boosted its position in Pfizer by 4.9% during the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock worth $6,886,849,000 after acquiring an additional 11,099,024 shares during the period. Marshall Wace LLP lifted its holdings in shares of Pfizer by 279.3% in the second quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock valued at $150,481,000 after buying an additional 8,378,173 shares during the period. Swedbank AB acquired a new stake in shares of Pfizer in the first quarter valued at $172,902,000. Pzena Investment Management LLC lifted its holdings in shares of Pfizer by 181.6% in the first quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock valued at $212,855,000 after buying an additional 4,947,000 shares during the period. Finally, FIL Ltd lifted its holdings in shares of Pfizer by 97.1% in the fourth quarter. FIL Ltd now owns 7,582,518 shares of the biopharmaceutical company’s stock valued at $218,301,000 after buying an additional 3,734,595 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on PFE. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Wells Fargo & Company upped their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. UBS Group upped their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Thursday. Nine investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Stock Performance

PFE opened at $28.35 on Friday. The company has a market cap of $160.65 billion, a PE ratio of -472.50, a price-to-earnings-growth ratio of 1.25 and a beta of 0.67. The stock has a 50-day moving average of $29.21 and a 200-day moving average of $28.31. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $34.08. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.67 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.